2000年Mayo Clinic 研究小组报道了终末期肝病评分模型（Model for end-stage liver disease，MELD），开始用于预测肝 硬化患者TIPS治疗的后果[1]，其后的研究表明： MELD对酒精性肝病[2]、肝...
基于4个网页-相关网页
目的：应用MELD(终末期肝病评分模型)评价慢性重型肝炎的近期预后。
Objective: To evaluate the application of the Model for End-Stage Liver Disease (MELD) in predicting the short-term prognosis in patients with chronic severe viral hepatitis.
目的评价分子吸附再循环系统(MARS)治疗重型肝炎的临床疗效，应用终末期肝病评分模型(MELD)，观察它对重型肝炎预后的预测作用。
Objective to evaluate the efficiency of Molecular Adsorbents Recycling System (MARS) in the treatment of severe hepatitis and to study the clinical use of the Model for End-Stage Liver Diease (MELD).
探讨终末期肝病模型(MELD)评分系统对预测慢性重型乙型病毒性肝炎患者短期预后的临床应用价值。
To assess the value of the model for end-stage liver disease (MELD) on the short-term prognosis in the patients with chronic liver failure (chronic and severe hepatitis B).
应用推荐